In this issue of Clinical Cancer Research, a new development in adoptive T cell therapy experimental mouse tumor model is reported by Leisegang et al. (1).
In retrospect, the 1990s were considered a golden period for tumor immunology when many tumor antigens recognized by T cells were identified. The antigens reported by Boon and colleagues in both murine and human cancers (2, 3) were derived from genes that are over-expressed in cancer and fetal tissues (4) . The second class of unmutated antigens recognized by tumor-reactive T cells is tissue-specific antigens that are also found in tumor cells (5) . These unmutated tumor antigens were favored for cancer vaccines and cancer therapy because they are present in a high proportion of human cancers. However, the classical study by Prehn and Main (6) has cast a long shadow on the utility of the shared tumor antigen as their in vivo analysis showed that tumor rejection antigens are by and large individually specific. In supporting this notion, Ramarathinam et al. reported that, although multiple lineages of murine tumor cells P1A, the first unmutated tumor antigens to be identified, were not cross-protective (7). While cancer patients have a high frequency of T cells specific for unmutated antigens, these T cells were unable to control cancer growth (8) . Consistent with this notion, the first transgenic mice that expressed unmutated tumor antigen-specific TCR on all T cells were not able to reject tumors that express the antigen, P1A (9) . The poor therapeutic effect of these T cells may have been predicated because the host must have De novo identified neoantigens which have been explored for cancer vaccines but rarely for adoptive T cell therapy. Since a therapeutic vaccine has never been as successful as a preventive vaccine even in cases of viral infection, the impact of neoantigen-based vaccination is considerably less than that of immunotherapy using T cells that recognize the neoantigens. Obviously, more is needed to develop adoptive T cell therapy from 
